PD19-03 EFFECTIVENESS OF THE MEDICAL CHATBOT PROSCA TO INFORM PATIENTS ABOUT PROSTATE CANCER: RESULTS OF A RANDOMIZED CONTROLLED TRIAL

Abstract

You have accessJournal of UrologyProstate Cancer: Detection & Screening II (PD19)1 May 2024PD19-03 EFFECTIVENESS OF THE MEDICAL CHATBOT PROSCA TO INFORM PATIENTS ABOUT PROSTATE CANCER: RESULTS OF A RANDOMIZED CONTROLLED TRIAL Kilian Baumgärtner, Stefan Duensing, Markus Hohenfellner, and Magdalena Goertz Kilian BaumgärtnerKilian Baumgärtner , Stefan DuensingStefan Duensing , Markus HohenfellnerMarkus Hohenfellner , and Magdalena GoertzMagdalena Goertz View All Author Informationhttps://doi.org/10.1097/01.JU.0001009448.41537.64.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The use of AI-powered chatbots is increasingly finding application in healthcare. AI-based chatbots can act as automated conversational agents, capable of promoting health and providing education at any time. However, their potential in medical settings remains largely unexplored. In this study, we evaluated the chatbot "PROSCA" (prostate cancer communication assistant), which was developed by urologists in Germany and SAP SE. The chatbot's purpose was to provide men facing prostate cancer diagnosis with informative, educational, and supportive assistance. METHODS: The chatbot was developed to provide information on prostate diseases, diagnostic tests for prostate cancer detection, stages, and treatment options. In this randomized controlled trial, patients were either provided with the chatbot or randomized to the control group (1:1). A total of 112 men were included, of which 103 gave feedback at the end of the study by filling out a standardized questionnaire on usage and usability, perceived benefits, and potential for improvement. RESULTS: In the chatbot group, patients' need for information over time decreased significantly more than in the control group (p=0.03). In the chatbot group, 42 of 54 men (78%) used PROSCA. Of them, 73% agreed that the chatbot improved their informedness about prostate cancer and 91% of patients would use the chatbot again. CONCLUSIONS: Through the introduction of the chatbot PROSCA, we created and evaluated an innovative evidence-based health information tool in the field of prostate cancer, allowing targeted support for doctor-patient communication and offering great potential in raising awareness, patient education, and support. Our results suggest that the chatbot PROSCA is well accepted by patients and benefits them as an additional information tool during prostate cancer diagnosis. The use of medical chatbots could help to satisfy patients´ need of information and integrate patients more in complex clinical procedures. Download PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e440 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Kilian Baumgärtner More articles by this author Stefan Duensing More articles by this author Markus Hohenfellner More articles by this author Magdalena Goertz More articles by this author Expand All Advertisement PDF downloadLoading ...

Ähnliche Arbeiten